Assembly Biosciences Inc. (ASMB)
$33.70
$-1.10
(-3.16%)
As on 28-Aug-2026 13:32EDT
Market cap
$700 Mln
Revenue (TTM)
$75 Mln
P/E Ratio
27.1
P/B Ratio
2.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0
-
Face value
--
-
Shares outstanding
20,360,596
10 Years Aggregate
CFO
$-433.79 Mln
EBITDA
$-614.58 Mln
Net Profit
$-670.38 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
| -0.9 | 30.1 | 23.0 | 30.2 | 46.5 | -5.2 | -8.0 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
| 115.5 | 59.7 | -36.9 | -44.2 | -61.5 | -70.4 | -9.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
|
33.7 | 700.0 | 74.8 | 0.0 | -0.1 | -0 | 27.1 | 2.2 |
| 17.6 | 6,238.0 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 188.9 | |
| 200.5 | 10,883.2 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 130.9 | |
| 77.1 | 15,932.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.8 | 13,215.0 | 830.8 | 54.9 | 3.2 | 8.1 | 271.7 | 18.7 | |
| 12.1 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.1 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 279.9 | 5,707.4 | 290.5 | 197.2 | 82.5 | 19.9 | 29.6 | 5.9 | |
| 68.5 | 6,142.1 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 31.5 | |
| 141.4 | 9,129.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 20.5 |
Shareholding Pattern
View DetailsAbout Assembly Biosciences (ASMB)
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are... in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Read more
-
CEO, President & Director
Mr. Jason A. Okazaki
-
CEO, President & Director
Mr. Jason A. Okazaki J.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Assembly Biosciences (ASMB)
What is the current share price of Assembly Biosciences Inc (ASMB) Today?
The share price of Assembly Biosciences Inc (ASMB) is $33.70 (NASDAQ) as of 28-Aug-2026 13:32 EDT. Assembly Biosciences Inc (ASMB) has given a return of 46.53% in the last 3 years.
What is the current PB & PE ratio of Assembly Biosciences Inc (ASMB)?
The P/E ratio of Assembly Biosciences Inc (ASMB) is 27.07 times as on 21-Aug-2026, a 27 discount to its peers’ median range of 37.31 times.
The P/B ratio of Assembly Biosciences Inc (ASMB) is 2.23 times as on 21-Aug-2026, a 71 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-62.28 |
1.84 |
2024 |
-2.58 |
3.11 |
2023 |
-0.07 |
0.11 |
2022 |
-0.06 |
0.06 |
2021 |
-0.08 |
0.06 |
What is the 52 Week High and Low of Assembly Biosciences Inc (ASMB)?
The 52-week high and low of Assembly Biosciences Inc (ASMB) are Rs 39.71 and Rs 20.23 as of 30-Aug-2026.
What is the market cap of Assembly Biosciences Inc (ASMB)?
Assembly Biosciences Inc (ASMB) has a market capitalisation of $ 700 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Assembly Biosciences Inc (ASMB)?
Before investing in Assembly Biosciences Inc (ASMB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.